We work on drug discovery by combining our proprietary global top level antibody engineering and cyclic peptide technology and biological hypothesis of disease causing mechanism to solve the unmet medical needs.

Switch Antibody™

While conventional antibody binds to target antigen in both tumor and normal tissues. Switch-Ig™ enables binding of antibody to target antigen only within tumor environment, and enables more effective and safer antibody therapeutics in cancer immunotherapy. This is achieved by our proprietary antibody engineering technology that allows antibody to only bind to the target antigen in the presence of extracellular adenosine triphosphate which is abundantly present in tumor microenvironment. Our first Switch Antibody™, STA551, is now being tested in clinical study, and we have multiple Switch Antibody™ projects in the drug discovery stage.

Reference Article:

Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation

Cancer Discovery, Published Online First August 25, 2020

Source Link: Cancer Discovery
< Back